IL-2
Interleukin-2 (IL-2) is a key cytokine regulating T cell proliferation, differentiation, and survival[1]. Mechanistically, IL-2 signals through the heterotrimeric IL-2 receptor complex, activating the JAK1/3-STAT5 pathway to induce transcription of genes critical for T cell expansion and function[1]. In disease models, IL-2 has been shown to drive regulatory T cell (Treg) expansion, contributing to immune homeostasis and suppression of autoimmunity, while its dysregulation is implicated in cancer and chronic inflammatory conditions[1]. Compared with related γ-chain cytokines, IL-2 exhibits unique receptor specificity and distinct downstream signaling kinetics, leading to selective activation of Tregs versus effector T cells[1]. Experimentally, IL-2 stimulation induces expression and unconventional secretion of IL-32β from T cells, highlighting a functional crosstalk between IL-2 signaling and proinflammatory cytokine networks[1]. Agonists and inhibitors of IL-2 or its receptor have been utilized to manipulate immune responses, providing platforms for preclinical models of autoimmunity, cancer immunotherapy, and T cell functional studies[1]. Therefore, IL-2 serves as both a central immunoregulatory factor and a practical tool for experimental modulation of T cell-mediated immunity[1].
-
IL-2 Related Products (115)
Related Products (115)
-
Recombinant Proteins (22)
-
PTPN22-IN-3
0 ImagesCat. No.: HY-184931PTPN22-IN-3 is a potent, selective, and orally active inhibitor of PTPN22 with an IC50 of 0.49 μM and a Ki of 0.28 μM. PTPN22-IN-3 exhibits over 14-fold selectivity against a broad panel of PTPs and shows no significant inhibition against SRC/CSK kinases or IDO1/Arginase metalloenzymes. PTPN22-IN-3 enhances TCR signaling, increases IL-2 expression and secretion, and promotes mouse splenic T cell proliferation. In immune-competent C57BL/6J mice, PTPN22-IN-3 suppresses MC38 syngeneic tumor growth and synergizes with Pembrolizumab (anti-PD-1) (HY-P9902A) therapy. PTPN22-IN-3 can be used for the study of colorectal cancer and other solid tumors responsive to T cell-mediated anti-tumor immunity.
-
RS-0481
0 ImagesCat. No.: HY-123221CAS No.: 134931-74-1RS-0481 is an orally active lymphocyte population function restorer. RS-0481 enhances IL-2 production activity. RS-0481 can re-establish the function of certain lymphoid cell populations impaired by the presence of a growing tumor in an animal. RS-0481 markedly augments the tumor-specific cytotoxic T lymphocytes, TDTH, and the nonspecific lymphokine-activated-killer-cell-like cell responses.
-
IKZF2-degrader 5
0 ImagesCat. No.: HY-182945IKZF2-degrader 5 is a highly efficient, highly selective, rapidly acting, and orally active IKZF2 molecular glue degrader. IKZF2-degrader 5 induces IKZF2 degradation via the Cullin-CRBN-dependent pathway. IKZF2-degrader 5 promotes the production of pro-inflammatory IL-2. IKZF2-degrader 5 attenuates the immunosuppressive function of regulatory T cells (Tregs). IKZF2-degrader 5 triggers rapid, significant, and sustained IKZF2 degradation in the spleen and thymus of mice. IKZF2-degrader 5 inhibits tumor growth. IKZF2-degrader 5 can be used for the research of B16F melanoma.
-
HPN601
0 ImagesCat. No.: HY-P992370HPN601 is a monoclonal antibody targeting CD326/EPCAM, as well as a protease-activated EpCAM-targeted T cell engager. HPN601 binds to EPCAM, CD3e and albumin, and induces T cell-mediated tumor cell killing. HPN601 significantly reduces the release levels of IFN-γ, IL-2, IL-6, and IL-10. HPN601 can be used for relevant research on cancers such as breast cancer and gastric cancer.
-
Myelopeptide-2
0 ImagesCat. No.: HY-P3736CAS No.: 137833-31-9Synonyms: MP-2Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research.
-
CD28-IN-1
0 ImagesCat. No.: HY-175780CAS No.: 1465291-19-3CD28-IN-1 (Compound 19MS-5) is a CD28 inhibitor with a KD of 12.48 μM. CD28-IN-1 has a superior binding capacity to CD28 and potently inhibits CD28-B7 interactions. CD28-IN-1 inhibits CD28-driven immune activation and suppresses cytokine (IFN-γ, IL-2 and TNF-α) production in primary human T cells co-cultured with tumor spheroids and human epithelial tissues. CD28-IN-1 can be used for tumor immunity research.
-
REGN-10597
0 ImagesCat. No.: HY-P992161REGN-10597, composed of an anti-huPD-1-targeting antibody and IL2Ra-IL2 moiety, is a PD-1-dependent IL-2 agonist. REGN-10597 binds PD-1 to deliver masked native IL-2 to PD-1+ T cells, engaging trimeric IL-2 receptors to activate downstream signaling. REGN-10597 can be used for the research on melanoma, prostate cancer, colorectal cancer, and ovarian cancer.
-
5-Androstenetriol
0 Images5-Androstenetriol is a systemic radiation protector that can boost the host's immunity, leading to increased resistance to infections. 5-Androstenetriol can raise levels of IL-2, IL-3, and IFN, while countering the immunosuppressive effects of Hydrocortisone (HY-N0583).
-
23ME-00610
0 ImagesCat. No.: HY-P99216223ME-00610 is a humanized effector-function-null IgG1 antibody targeting CD200R1, with a Kd of <0.1 nM for hCD200R1. 23ME-00610 blocks the binding of CD200 to CD200R1 and inhibits the recruitment of the downstream adaptor protein DOK2 to CD200R1. 23ME-00610 restores IL-2 production suppressed by CD200. 23ME-00610 induces cytokine production in cells. 23ME-00610 enhances cell-mediated tumor cell killing in vitro. 23ME-00610 can be used for melanoma research.
-
TCR-IN-1
0 ImagesCat. No.: HY-180608CAS No.: 2375042-31-0
-
HPK1-IN-69
0 ImagesCat. No.: HY-182238CAS No.: 3095423-83-6HPK1-IN-69 is an orally active HPK1 inhibitor with an IC50 of 1.7 nM. HPK1-IN-69 inhibits the HPK1-mediated TCR signaling pathway, reduces the phosphorylation level of SLP76, and promotes the release of IL-2. HPK1-IN-69 exhibits in vivo anti-tumor activity in mouse models. HPK1-IN-69 can be used for the research of colorectal cancer and MC38 syngeneic tumors.
-
NFAT-133
0 ImagesCat. No.: HY-N16431CAS No.: 165133-85-7NFAT-133 is an aromatic polyketide with immunosuppressive and antidiabetic activity. NFAT-133 activates the AMPK pathway, promoting glucose uptake in L6 muscle fibers, thereby resisting diabetes. NFAT-133 inhibits the transcriptional activity of activated T-cell nuclear factor (NFAT), thereby suppressing the expression of IL-2 and the proliferation of T cells, demonstrating an immunosuppressive effect. NFAT-133 does not exhibit antibacterial activity or cytotoxicity, but it can weaken the production of NO in RAW264.7 cells induced by Lipopolysaccharide (LPS) (HY-D1056).
-
M802
0 ImagesCat. No.: HY-P992401M802 is an anti-HER2/CD3 bispecific antibody, with a Kd of 0.578 nM for human HER2 and a Kd of 71.2 nM for human CD3. M802 inhibits the PI3K/AKT and MAPK signaling pathways, suppresses tumor cell proliferation, activates caspase-3, and promotes tumor cell apoptosis (apoptosis). M802 recruits and activates CD3-positive immune cells, mediates cytotoxicity against HER2-positive tumor cells, and induces immune cells to secrete IFN-γ, TNF-α, IL-2 and IL-6. M802 exhibits anti-tumor efficacy in mice with gastric cancer xenografts. M802 can be used in research related to HER2-positive breast cancer, HER2-positive gastric cancer and other cancers. The recommended isotype control is human IgG1 kappa (HY-P99001).
-
IBI-325
0 ImagesCat. No.: HY-P991634IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.
-
HPK1-IN-65
0 ImagesCat. No.: HY-179338HPK1-IN-65 is a selective and orally active HPK1 inhibitor with an IC50 value of < 5 nM. HPK1-IN-65 inhibits HPK1 kinase activity and displays 1257-fold selectivity over the MAP4K kinase family member GLK. HPK1-IN-65 exhibits an IC50 of 92.3 nM for inhibiting pSLP76 phosphorylation. HPK1-IN-65 demonstrates an EC50 of 398 nM for stimulating IL-2 production. HPK1-IN-65 inhibits TCR-induced phosphorylation of SLP76 at Ser376 in a dose-dependent manner. HPK1-IN-65 can be further utilized for colorectal cancer research.
-
GNE-7056
0 ImagesCat. No.: HY-189477CAS No.: 1557236-81-3GNE-7056 is an orally active interleukin-2-inducible T-cell kinase (ITK) inhibitor with a Ki of 0.2 nM against human kinase, and exhibits high selectivity over LCK kinase. GNE-7056 inhibits PLCγ-1 phosphorylation, suppresses the production of IL-2, IL-4, IL-13 and TH2 cytokines, reduces CD4+ T-cell proliferation, and inhibits activation-induced cell death of CD4+ T cells by decreasing the abundance of FasL. GNE-7056 can be used in asthma-related research.
-
Immuno modulator-1
0 ImagesCat. No.: HY-153952CAS No.: 2757469-20-6Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM.
-
PROTAC IRAK4 degrader-14
0 ImagesCat. No.: HY-181708CAS No.: 3113890-51-7
-
DF6002
0 ImagesCat. No.: HY-P991436Synonyms: BMS-986415
-
KZR-8445 TFA
0 ImagesCat. No.: HY-P10466AKZR-8445 TFA, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 TFA binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 TFA inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 TFA inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 TFA blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 TFA can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection.
